EGFR and central nervous system cancer: Over the last decade, isocitrate dehydrogenase (IDH) mutation status, O6-methylguanine-DNA methyl-transferase (MGMT) promoter methylation, epidermal growth factor receptor (EGFR) alterations, and 1p19q codeletion have been identified as biomarkers and play a central role in the classification of gliomas and treatment decisions (6–9).